Liquid Encapsulation Utilizing An Emulsion Or Dispersion To Form A Solid-walled Microcapsule (includes Liposome) Patents (Class 264/4.1)
  • Patent number: 10772807
    Abstract: Lipid microcapsules are described that can include at least one irritant active substance, more specifically a retinoid, in a soluble form. Also described, are pharmaceutical compositions comprising the same, and methods for the production thereof. A method of using the composition to treat dermatological pathologies is also described.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: September 15, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Claire Mallard, Carole Dubayle
  • Patent number: 10759843
    Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 1, 2020
    Inventors: Santos Susin, Pierre Launay, Philippe Karoyan, Helene Merle-Beral
  • Patent number: 10759832
    Abstract: Peptides having a human minute binding protein-2 (HDM-2) targeting sequence that target the human minute binding protein-2, fusion proteins having a HDM-2 targeting sequence, and methods of using the peptides and proteins to treat cancer are described.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: September 1, 2020
    Assignee: SLH Innovations LLC
    Inventor: Matthew R. Pincus
  • Patent number: 10736845
    Abstract: A pharmaceutical composition can include a plurality of liposomes comprising docetaxel and doxorubicin. In various embodiments, a liposome can include (i) an active pharmaceutical ingredient (API) comprising docetaxel and doxorubicin; (ii) a lipid layer comprising an unsaturated phospholipid, a cholesterol, a cationic lipid, and preferably a pegylated phospholipid; and (iii) an aqueous interior, wherein the docetaxel is in the lipid layer and the doxorubicin is crystallized in the aqueous interior. The liposomes can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: August 11, 2020
    Assignee: Cureport Inc.
    Inventors: De-Min Zhu, Guoqiang Chen
  • Patent number: 10729748
    Abstract: Undue scarring of healing wounds is decreased and/or the relapse rate of wounds is lowered by applying a composition that includes hemoglobin to the wound area. At least 90% of the hemoglobin in the composition is provided in CO-charged form.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: August 4, 2020
    Assignee: MÖLNLYCKE HEALTH CARE AB
    Inventor: Michael Sander
  • Patent number: 10723780
    Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 28, 2020
    Assignees: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
  • Patent number: 10723765
    Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Xaa1-Xaa2-Thr3-Xaa4-Ser5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-) and pharmaceutically acceptable salts thereof, with Xaa1, Xaa2, Xaa4, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12 and Xaa13 being amino acid residues which are defined in the description and the claims, have elastase inhibitory properties, especially against human neutrophil elastase, and can be used for preventing infections or diseases related to such infections in healthy individuals or for slowing infections in infected patients. The compounds of the invention can further be used where cancer, or immunological diseases, or pulmonary diseases, or cardiovascular diseases, or neurodegenerative diseases, or inflammation, or diseases related to inflammation, are mediated or resulting from elastase activity. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: July 28, 2020
    Assignee: POLYPHOR AG
    Inventors: Frank Otto Gombert, Daniel Obrecht, Odile Sellier-Kessler
  • Patent number: 10716774
    Abstract: Isotretinoin compositions having improved bioavailability are disclosed. The compositions are oral formulations containing isotretinoin, a lipid excipient and a cosolvent, wherein the ratio of isotretinoin to the lipid excipient is from about 1:1.2 to about 1:1.6. The compositions can be in the form of a pharmaceutically acceptable oral dosage form such as a capsule or compressed tablet wherein the isotretinoin is adsorbed onto blended particles of a cellulosic polymer and silicon dioxide in combination with a lipid excipient such as soy phosphatidylcholine and a cosolvent such as propylene glycol. Methods of preparing the compositions and methods of treatment using the compositions are also disclosed.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 21, 2020
    Assignee: YALE PHARMACEUTICALS LLC
    Inventor: Basavaraj Siddalingappa
  • Patent number: 10687541
    Abstract: Coconut oil, coconut oil blends that are high in MCTs such as LouAna® liquid coconut oil, pure MCT oils, and Omega-3 oils may be emulsified to create an emulsified oil or blend that may take the form of a creamy shot or a cream substitute. These oils and/or blends may be emulsified using an emulsifier that may be selected from the following: sunflower lecithin, sodium stearoyl lactylate (SSL), or a combination of sunflower lecithin and SSL. By emulsifying these oils/oil blends, a good tasting creamy shot or a cream substitute can be formed.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: June 23, 2020
    Inventor: Jesse Windrix
  • Patent number: 10653735
    Abstract: Use of Mesembryanthemum crystallinum L. callus extract in the manufacture of a medicament or a skin care product, wherein the medicament or skin care product is for at least one of delaying skin cell aging, nursing skin, repairing skin, treating skin cancer, and preventing skin cancer.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: May 19, 2020
    Assignee: TCI CO., LTD.
    Inventors: Yung-Hsiang Lin, Wei-Wen Kuo, I-Hui Chen, Yi-Chun Chen, Hui-Hsin Shih, Yun-Ching Tsai
  • Patent number: 10653786
    Abstract: Provided herein relates to compositions and methods for lubrication of a surface. The surface amenable to the compositions and methods described herein can be a non-biological surface, a biological surface, or a combination thereof. In some embodiments, the composition comprising a phospholipid-coated silk microsphere can be used for lubrication of a surface. In some embodiments, the composition comprising a phospholipid-coated silk microsphere can be used for joint lubrication, e.g., for treatment of joint disorders such as arthritis.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: May 19, 2020
    Assignees: TRUSTEES OF TUFTS COLLEGE, Tulane Educational Fund
    Inventors: David L. Kaplan, Xiaoqin Wang, Vijay John, Noshir Pesika, Rubo Zheng
  • Patent number: 10639348
    Abstract: The peptides of the invention are of formula (I) or (IV). The peptides of the invention are useful in the treatment of cancer.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 5, 2020
    Assignee: IDP DISCOVERY PHARMA, S.L.
    Inventors: Santiago Esteban Martín, Laura Nevola
  • Patent number: 10640565
    Abstract: The present invention provides novel humanized anti-human C-C chemokine receptor type 7 (CCR7) antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: May 5, 2020
    Assignee: PepMab B.V.
    Inventors: Jaap Willem Back, Ronald Boshuizen, Wouter Cornelis Puijk, Johan Turkstra, Klaus Heinrich Schwamborn
  • Patent number: 10617128
    Abstract: Coconut oil, coconut oil blends that are high in MCTs such as LouAna® liquid coconut oil, pure MCT oils, Omega-3oils, cannabidiol (CBD), hemp extract, tree nut oil, macadamia oil, almond oil, cashew oil, avocado oil, docosahexaenoic acid (DHA), fish oil, and/or conjugated linoleic acid (CLA) may be emulsified to create an emulsified oil or blend that may take the form of a creamy shot or a cream substitute. These oils and/or blends may be emulsified using an emulsifier that may be selected from the following: sunflower lecithin, sodium stearoyl lactylate (SSL), acacia gum, beta-cyclodextrin, and combinations of same. By emulsifying these oils/oil blends, a good tasting creamy shot or a cream substitute can be formed.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: April 14, 2020
    Inventor: Jesse Windrix
  • Patent number: 10611797
    Abstract: A peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1: Asn-Tyr-Pro-Gln-Arg-Pro, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient are disclosed. When cancer cells are treated with the peptide and the pharmaceutical composition containing the same, the peptide can specifically bind to CP2c by passing, with very high stability, through the cell membrane and can inhibit the DNA binding ability of CP2c, thereby disturbing CP2c-mediated cancer cell-specific transcriptional activity through the inhibition of CP2c activity. Thus, the peptide and pharmaceutical composition containing the same can be effectively used for specifically treating only cancer cells and can be utilized for cancer prevention and as a dietary supplement additive therefor.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: April 7, 2020
    Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
    Inventors: Chul Geun Kim, Min Young Kim, Chan Gil Kim, Ho Chul Kang, Ji Hyung Chae, Su Jae Lee, Eun Jung Baek, Chae Ok Yun, Jin Won Lee, Young Su Lim, Je Min Choi, Dae Hyun Ha, Hyung Sik Won, Seung Han Son
  • Patent number: 10548841
    Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: February 4, 2020
    Assignee: OPKO Pharmaceuticals, LLC
    Inventors: Arturo Santos, Phillip Frost
  • Patent number: 10543274
    Abstract: The present invention is directed to novel lyophilized pharmaceutical preparations comprising a cytotoxic dipeptides such as melphalan flufenamide and one or more excipient(s) selected from the group comprising a polysorbate; a polyethylene glycol; ?-cyclodextrin; ocyclodextrin; hydroxypropyl-?-cyclodextrin; sulfobutylether-?-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremophor EL; Dimethyl sulfoxide; D-mannitol; Trehalose; Sucrose and an amino acid. This preparation may be further formulated and is useful in cancer therapy.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 28, 2020
    Assignee: ONCOPEPTIDES AB
    Inventors: Jack Spira, Fredrik Lehmann
  • Patent number: 10537623
    Abstract: Provided is a method for inducing immunity for therapy of a cancer(s). The method includes the step of administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, the recombinant vector(s) being capable of expressing the polypeptide(s) in vivo: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a). Further, an in vitro method for preparing an antigen-presenting cell is provided. The method includes the step of contacting the antigen-presenting cell with the at least one polypeptide selected from: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 22, or 24; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a).
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: January 21, 2020
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Akira Kurihara, Fumiyoshi Okano
  • Patent number: 10539551
    Abstract: A previously unrecognized fundamental property of ?1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with Human Immunodeficiency Virus-1 (HIV-1) infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, cell surface Human Leucocyte Elastase (HLEcs) and Lipoprotein Receptor-related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: January 21, 2020
    Assignees: The Institute for Human Genetics and Biochemistry
    Inventor: Cynthia L. Bristow
  • Patent number: 10517925
    Abstract: Provided are a composition including a Kang AI 1 (KAI1) polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, KAI1, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases KAI1 or in which KAI1 is forcefully increased, a method using a KAI1 protein, or a method for inhibiting a Src-Pkc pathway provoking the degradation of KAI1. Further, the subject matter can identify the severity of a cancer patient by identifying the expression of KAI1 in a pericyte.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: December 31, 2019
    Assignee: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION
    Inventors: Hyo-Soo Kim, Jin Hur, Jae Il Choi
  • Patent number: 10519434
    Abstract: Collection devices and kits for biological sample collection include a biologic sample collection device having a hydrophilic swab matrix that includes a modified polycaprolactone (PCL). Methods of production and use thereof are also described herein. The biologic sample collection devices, kits and methods described herein are used to collect a biologic sample (e.g., blood, buccal cells, etc.) and to enable extraction of nucleic acids (e.g., DNA) from that biologic sample so that the nucleic acids can be analyzed (e.g., sequencing and subsequent analyses of DNA).
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: December 31, 2019
    Inventors: Jeff Morhet, Thomas Kindt, Franco Ferrari, Vasana Maneeratana, Frederic Zenhausern, Sean Grandfield, Beverly L. Wolgast, Alistair McIntyre
  • Patent number: 10507242
    Abstract: The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGF?) antagonist in combination with capecitabine and ixabepilone to treat breast cancer.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: December 17, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Jay Harper, Scott Lonning, Frank Hsu
  • Patent number: 10500283
    Abstract: The present investigation relates to entrapment of carbohydrate antigen such as Vi polysaccharide of Salmonella typhi in poly (DL) lactide (PDLLA) and polylactide-co-glycolide (PLGA) polymer particles. The formulated product not only elicits primary antibody titers from single dose application but also evokes memory antibody titer against the T independent antigen.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: December 10, 2019
    Assignee: National Institute of Immunology
    Inventors: Anish Chakkumkal, Amulya Kumar Panda
  • Patent number: 10500227
    Abstract: Echogenic liposomes (ELIP) formulated with an at least partially pegylated phospholipid bi-layer shell, encapsulated nitric oxide, and encapsulated perfluorocarbon of the formula CxFy in a ratio of about 1:1 by volume, wherein X is greater than or equal to 3, are disclosed, along with methods for treating a patients suffering from cardiovascular disease by administering the ELIP at a site remote from the target diseased section, monitoring presence of the ELIP at the target diseased section, and administering ultrasound upon detection of presence such that bioactive NO is released at the target diseased section.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 10, 2019
    Assignee: University of Cincinnati
    Inventors: Christy Holland, Jason Raymond, Jonathan Sutton
  • Patent number: 10494412
    Abstract: The present invention relates to novel peptides, which impair PBX-dependent regulation of gene transcription and thus have utility in the treatment or prevention of disorders in which aberrant cell division occurs.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: December 3, 2019
    Assignee: HOX THERAPEUTICS LIMITED
    Inventor: Richard Morgan
  • Patent number: 10485858
    Abstract: Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, route of administration for the regimens.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: November 26, 2019
    Assignee: Stemline Therapeutics, Inc.
    Inventors: Ivan Bergstein, Christopher Brooks, Thomas P. Cirrito
  • Patent number: 10478470
    Abstract: The present invention relates to a pharmaceutical composition containing leuprolide acetate and having both immediate and sustained release properties and, more specifically, to a pharmaceutical composition in which, on the basis of the total weight of active ingredients, leuprolide as an immediate release preparation is contained in 0.001 wt % to 25 wt %; and leuprolide contained in microspheres of a sustained release preparation is contained in 75 wt % to 99.999 wt %. The pharmaceutical composition of the present invention is characterized by satisfying both a drug immediate release property so as to realize the prompt exposure to a sufficient amount of drug at the early stage for expression of medicinal effects and a drug sustained release property for four weeks or longer, and the pharmaceutical composition is effective in the prevention and treatment of sex hormone-dependent positive or malignant diseases.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 19, 2019
    Assignee: SK CHEMICALS CO., LTD.
    Inventors: Hong Kee Kim, Kyu Ho Lee, Seok Hyun Hong, Yong-kyu Kwak, Ho Chul Shin, Hun-Teak Kim
  • Patent number: 10471016
    Abstract: The invention relates to microparticles comprising a crosslinked gel and methods for making and using same.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: November 12, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: David J. Mooney, David A. Weitz, Stefanie Utech, Radivoje Prodanovich, Esther Amstad, Raluca Ostafe, Angelo S. Mao, Connie Chang Wilking, Huanan Wang
  • Patent number: 10472395
    Abstract: Provided are cyclic peptide analogs, conjugates comprising such compounds, and pharmaceutical compositions comprising such compounds and conjugates, and methods of treating cancer with such compounds and conjugates.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: November 12, 2019
    Assignee: Sirenas LLC
    Inventors: Venkat Rami Reddy Macherla, Alexander Wayne Schammel, Ippei Usui, Elizabeth Paige Stout, Jacob Neal Beverage, Bryan Junn Lee, Steven Bruce Cohen
  • Patent number: 10463725
    Abstract: Provided is a method for inducing immunity for therapy of a cancer(s). The method includes the step of administering to an individual with cancer at least one polypeptide selected from the polypeptides (a) or (b) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at least one polypeptide, the recombinant vector(s) being capable of expressing the polypeptide(s) in vivo: (a) a polypeptide in any one of the amino acid sequences of SEQ ID NOs: 2, 4, 8, 10 and 12; and (b) a polypeptide having a sequence identity of not less than 95% to the polypeptide (a).
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: November 5, 2019
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Akira Kurihara, Fumiyoshi Okano
  • Patent number: 10434046
    Abstract: A microcapsule composition comprising at least one polymer substantially disposed as a semi-permeable shell around a buffered solution and at least one therapeutic agent, wherein the therapeutic agent permeates the shell, and wherein the composition is suitable for topical epithelial cells of mammal.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: October 8, 2019
    Assignee: Premier Dental Products Company
    Inventors: Mark A. Latta, Stephen M. Gross, William A. McHale
  • Patent number: 10434047
    Abstract: A microcapsule composition comprising at least one polymer substantially disposed as a semi-permeable shell around an aqueous buffered solution and at least one agent, wherein the agent permeates the shell, and wherein the composition is suitable for delivery to a mammal.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: October 8, 2019
    Assignee: Premier Dental Products Company
    Inventors: Mark A. Latta, Stephen M. Gross, William A. McHale
  • Patent number: 10413511
    Abstract: The present invention relates to the preparation of liposomes with enhanced loading capacity for pharmaceutically and/or diagnostically active agents and/or cosmetic agents which are substantially solubilized by the liposomal membranes, to liposome dispersions with enhanced stability with respect to release of the active agent and/or cosmetic agent from the liposomes obtainable by the process, and to pharmaceutical or cosmetic compositions comprising said stabilized liposome dispersions. The preparation may involve dehydration and rehydration steps of liposome dispersions which may be carried out by spray drying.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: September 17, 2019
    Assignee: SynCore Biotechnology Co., Ltd.
    Inventors: Heinrich Haas, Ursula Fattler
  • Patent number: 10403834
    Abstract: A flexible display device including a hard coating layer, the hard coating layer containing first hard coating oligomers, second hard coating oligomers having greater molecular weights than the first hard coating oligomers, a cross-linker, and a photoinitiator. The first hard coating oligomers may maintain the hardness of the hard coating layer and the second hard coating oligomers may improve the flexibility of the hard coating layer, such that damage to the hard coating layer may be prevented or reduced even when the flexible display device is bent.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: September 3, 2019
    Assignee: Samsung Display Co., Ltd.
    Inventors: Youngsang Park, Chulho Jeong, Ahyoung Kim
  • Patent number: 10400012
    Abstract: Peptides having a human minute binding protein-2 (HDM-2) targeting sequence are capable of targeting the human minute binding protein-2. Peptides having an HDM-2 targeting sequence may be used to treat cancer.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 3, 2019
    Assignee: SLH Innovations LLC
    Inventor: Matthew R. Pincus
  • Patent number: 10383900
    Abstract: This disclosure provides, inter alia, systems and methods for storage and delivery of ammonia oxidizing bacteria, and preparations comprising ammonia oxidizing bacteria. The ammonia oxidizing bacteria may be provided in a container or a kit, with one or more other components that may enhance delivery. The systems and methods herein may be used, for instance, to treat diseases associated with low nitrite levels, skin diseases, and diseases caused by pathogenic bacteria.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: August 20, 2019
    Assignee: AOBIOME LLC
    Inventors: James Heywood, Spiros Jamas, David R. Whitlock, Larry Weiss
  • Patent number: 10364280
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERTX4AX6WEIX10X11LPNLX16X17X18QX20GAFIX25X26LHD. The present disclosure also relates to the use of such a PD-L1 binding polypeptide a prognostic and/or diagnostic agent as well as a therapeutic agent.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: July 30, 2019
    Assignee: AFFIBODY AB
    Inventor: Elisabet Wahlberg
  • Patent number: 10342830
    Abstract: This document provides methods and materials for treating lung conditions induced by inhalable insulin therapy. For example, compositions including a dried amnion tissue preparation and/or a dried stem cell preparation as well as methods for using such compositions to treat inhalable insulin induced lung conditions are provided.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: July 9, 2019
    Inventor: Gary M. Petrucci
  • Patent number: 10322191
    Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: June 18, 2019
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
  • Patent number: 10314946
    Abstract: Hydrogels and composite material containing hydrogels and liposomes dispersed therein, which exhibit a reduced friction coefficient compared to neat hydrogels or composites containing hydrogels, processes for preparing the same, and methods for using the same are disclosed.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: June 11, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Jacob Klein, Ronit Goldberg, Noa Iuster, Raya Sorkin
  • Patent number: 10308682
    Abstract: Disclosed herein are fibrillar molecular aggregates, which are morphologically and phenotypically similar to oligomers of aberrant proteins. The molecular aggregates, formed by self-assembly of small hydrophobic molecules, prevent the growth of microtubules. This unprecedented mechanism of “self-assembly to interfere with self-organization” allows inhibition of the growth of cancer cells.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: June 4, 2019
    Assignee: Brandeis University
    Inventors: Bing Xu, Yi Kuang
  • Patent number: 10307490
    Abstract: Described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a targeting agent. The composition can include a therapeutic agent. The therapeutic agent can be an antisense oligonucleotide (ASO). Exemplary ASOs are targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; or targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Also described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a therapeutic agent that is an ASO such as an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1 or an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Pharmaceutical formulations, methods of making the lipid nanoparticles, and methods of using the lipid nanoparticles, for example for treating cancers, are also disclosed.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: June 4, 2019
    Assignee: The Ohio State University
    Inventors: Robert J. Lee, Young Bok Lee, Deog Joong Kim, Chang Ho Ahn
  • Patent number: 10301506
    Abstract: A process for preparing polymer. An embodiment of a method includes generating a resin solution including a first reaction solvent and a polymer resin dissolved therein; deploying the resin solution into a precipitation solvent contained in a chamber of a reaction vessel, wherein deploying the resin solution includes generating droplets of the resin solution; disturbing a resulting mixture of the resin solution and the precipitation solvent, wherein the mixture produces a precipitate; and generating a polymer powder from the mixture, including isolating the precipitate from a remaining portion of the mixture, and drying the isolated precipitate.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: May 28, 2019
    Assignee: Cymer-Dayton, LLC
    Inventors: Limor Ben-Asher, David Edward Noga, Zhongliang Zhu, Anderson Bouton
  • Patent number: 10285405
    Abstract: The present disclosure provides a particulate matter comprising particles carrying an essentially dry combination of components comprising at least one natural oil and at least one surfactant, the components being selected such that upon contact with water, oil in water emulsion is formed. In particular, the emulsion formed is a stable emulsion, with stability of at least several hours, as observed by the lack of phase separation during that time.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: May 14, 2019
    Assignee: Nobactra Israel Ltd.
    Inventor: Giora Kritzman
  • Patent number: 10273267
    Abstract: ?-Hairpin peptidomimetics of the general formula cyclo(-Xaa1-Xaa2-Thr3-Xaa4-Ser5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-) and pharmaceutically acceptable salts thereof, with Xaa1, Xaa2, Xaa4, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10, Xaa11, Xaa12 and Xaa13 being amino acid residues of certain types which are defined in the description and the claims, have elastase inhibitory properties, especially against human neutrophil elastase, and can be used for preventing infections or diseases related to such infections in healthy individuals or for slowing infections in infected patients. The compounds of the invention can further be used where cancer, or immunological diseases, or pulmonary diseases, or cardiovascular diseases, or neurodegenerative diseases, or inflammation, or diseases related to inflammation, are mediated or resulting from elastase activity. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: April 30, 2019
    Assignee: POLYPHOR AG
    Inventors: Frank Otto Gombert, Daniel Obrecht, Odile Sellier-Kessler, Alexander Lederer, Christian Ludin, Manuella Schmitt-Billet, Steffen Weinbrenner
  • Patent number: 10258570
    Abstract: The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 ?m and 5 ?m, preferably between 0.2 ?m and 2.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: April 16, 2019
    Assignee: Lung Biotechnology Inc.
    Inventors: Tobias Gessler, Thomas Schmehl, Monika Rieger
  • Patent number: 10241045
    Abstract: Spectrally encoded microbeads and methods and devices for making and using spectrally encoded microbeads are provided. The disclosed methods and devices facilitate the preparation and use of microbeads containing multiple lanthanide nanoparticles, which microbeads have uniquely identifiable spectral codes. The disclosed microbeads, and the methods and devices for making and using same, find use in multiplexing and high-throughput biomarker analysis.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: March 26, 2019
    Assignee: The Regents of the University of California
    Inventors: Brian Cullen Baxter, Joseph L. Derisi, Polly M. Fordyce, Rachel E. Gerver, Rafael Gòmez-Sjöberg, Brett A. Helms, Kurt S. Thorn, Ronald N. Zuckermann
  • Patent number: 10232013
    Abstract: The preset invention relates to a new approach for treating a cancer, particularly a malignant tumor, a multidrug-resistant (MDR) cancer, a recurrent cancer or a metastatic cancer, using a specific cationic antimicrobial peptide (CAP), tilapia piscidin 4 (TP4), which is derived from Nile Tilapia (Oreochromis niloticus). Also provided is a method for treating a breast cancer, particularly triple negative breast cancer (TNBC) with TP4.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: March 19, 2019
    Assignee: Academia Sinica
    Inventors: Jyh-Yih Chen, Chen-Hung Ting
  • Patent number: 10220095
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: March 5, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD, TLC BIOPHARMACEUTICALS, INC
    Inventors: Pei Kan, Yun-Long Tseng, Han-Chun Ou, Chun-yen Lai
  • Patent number: 10214704
    Abstract: A lubricating oil comprises a base oil; and an anti-degradation additive comprising microcapsules, nanocapsules, or a combination comprising at least one of the foregoing; the microcapsules and the nanocapsules each independently having a core of a neutralizing material and a polymeric encapsulant configured to release the neutralizing material in an acidic environment by breaking crosslinks or hydrogen bonds in the polymeric encapsulant. The released neutralizing material can prevent the formation of viscous, high molecular weight molecules thus enhancing the lifetime of the lubricating oil and improving its reliability.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 26, 2019
    Assignee: BAKER HUGHES, A GE COMPANY, LLC
    Inventors: Darryl Ventura, Rostyslav Dolog, Oleg A. Mazyar, Valery Khabashesku, Qusai Darugar